Dr. Gregory P. Monohan, MD
Hematology (Hematology (Internal Medicine) Physician)
800 Rose Street, Cc446 Roach Bldg. Uk Hematology Clinic
Lexington, KY 40536
Who else practices at this address →
Fayette County includes mental health (15% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Kentucky College of Medicine (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 161
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2000Medical school: University of Kentucky College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
KY license 37946 -
Hematology & Oncology Physician
KY license 37946 -
Internal Medicine Physician
KY license 37946 -
Medical Oncology Physician
KY license 37946
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Kentucky Hospital Lexington, KY
- Baptist Health Corbin Corbin, KY
Medical groups
- Kentucky Medical Services Foundation, Inc (967 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 161
- Services billed
- 491
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 156 | 41 |
| Established patient office or other outpatient visit, 30-39 minutes | 131 | 77 |
| Established patient office or other outpatient visit, 40-54 minutes | 64 | 40 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 27 | 26 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 21 | 18 |
| New patient office or other outpatient visit, 45-59 minutes | 17 | 17 |
| New patient office or other outpatient visit, 60-74 minutes | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Lexington, KY | 388 |
| Dexamethasone Other prescribers in Lexington, KY | 188 |
| Lenalidomide | 153 |
| Revlimid (lenalidomide) | 97 |
| Pomalyst (pomalidomide) | 83 |
| Oxycodone Hcl Other prescribers in Lexington, KY | 69 |
| Gabapentin Other prescribers in Lexington, KY | 60 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Lexington, KY | 56 |
| Prochlorperazine Maleate Other prescribers in Lexington, KY | 55 |
| Brukinsa (zanubrutinib) | 36 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $129,567 in research payments for these studies, mostly to the institutions running them.
- A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT05730036 - Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specification (OOS) in patients with Multiple Myeloma
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.